Pharming Group reports financial results for the first quarter of 2022

Strong cash flow from operations supporting investments in leniolisib Strong cash flow from operations supporting investments in leniolisib LEIDEN,Netherlands , May 12, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company")(EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR)presents its (unaudited) financial report for the first quarter of the year ended31 March 2022.   Financial Summary Financial highlights Operational highlights Post-period...

Netherlands, 12/05/2022 (informazione.news - comunicati stampa - scienza e tecnologia)

LEIDEN, Netherlands , May 12, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) presents its (unaudited) financial report for the first quarter of the year ended 31 March 2022 .

 

For the remainder of 2022, the Company anticipates:

No further specific financial guidance for 2022 is provided.

Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands , and has employees around the globe who serve patients in over 30 markets in North America , Europe , the Middle East , Africa , and Asia-Pacific .

For more information, visit www.pharming.com.

Sijmen de Vries, CEO
T: +31 71 524 7400
E: investor@pharming.com

Victoria Foster Mitchell / Alex Shaw / Amy Byrne
T: +44 203 727 1000

Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

13:30 CET / 07:30 ET

Netherlands (Local)        085 888 7233
United Kingdom              0800 640 6441
United Kingdom (Local) 020 3936 2999
United States                    1 855 9796 654
United States (Local)      1 646 664 1960
All other locations          +44 20 3936 2999

https://webcast.openbriefing.com/pharming-q12022/

For the period ended 31 March 2022

For the period ended 31 March

 

For the period ended 31 March 

 

 

For the three months ended 31 March

 

Logo - https://mma.prnewswire.com/media/1778344/Pharming_Group_NV_Logo.jpg